Last reviewed · How we verify
IV Novolin R human insulin
Novolin R is a rapid-acting human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Novolin R is a rapid-acting human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus, Acute hyperglycemia and diabetic ketoacidosis (IV formulation).
At a glance
| Generic name | IV Novolin R human insulin |
|---|---|
| Also known as | Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ |
| Sponsor | State University of New York - Downstate Medical Center |
| Drug class | Insulin, rapid-acting human insulin |
| Target | Insulin receptor (INSR) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Human insulin mimics the body's natural insulin hormone by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into these cells and promoting glycogen synthesis while inhibiting gluconeogenesis. When administered intravenously, it provides rapid glucose control suitable for acute hyperglycemia management and perioperative settings. Novolin R is a recombinant human insulin produced through biotechnology.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
- Acute hyperglycemia and diabetic ketoacidosis (IV formulation)
Common side effects
- Hypoglycemia
- Injection site reactions
- Lipodystrophy
- Weight gain
- Hypokalemia
Key clinical trials
- Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes (PHASE1, PHASE2)
- 5 Versus 10 Units of Insulin in Hyperkalemia Management (PHASE4)
- Effect of High Dose Insulin on Infectious Complications Following Major Surgery (NA)
- Dexamethasone/Pancreatic Clamp P&F (PHASE1)
- Neural Mechanism of Aldosterone-induced Insulin Resistance (PHASE4)
- Pilot: Insulin Sensitivity/Management in Hyperglycemic Patients in Perioperative Period ESRD/Non-ESRD (PHASE4)
- Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery (PHASE4)
- Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: